类风湿关节炎患者肌少症患病率:横断面研究
本研究纳入978例类风湿关节炎(RA)患者,采用亚洲肌少症工作组(AWGS)2025标准诊断肌少症,患病率为18.6%。男性、较低BMI、较长病程、较高RF-IgM水平及较高泼尼松剂量与肌少症相关,而使用TNF抑制剂或托珠单抗可能降低其风险。
要点
- RA患者肌少症患病率为18.6%,应重视筛查。
- 男性、低BMI、长病程、高RF-IgM及高泼尼松剂量是危险因素。
- TNF抑制剂和托珠单抗使用与肌少症风险降低相关。
核心结论
- RA患者中肌少症患病率较高,为18.6%。
- 男性、较低BMI、较长病程、较高RF-IgM水平及较高泼尼松剂量是肌少症的关键危险因素。
- 使用托珠单抗和TNF抑制剂可能与降低肌少症发生率相关。
研究设计与样本
- 横断面研究,纳入978例符合2010年ACR/EULAR分类标准的RA患者。
- 平均年龄60.1±12.1岁(范围21-99岁),女性占86.4%。
- 肌少症诊断基于AWGS 2025共识,采用生物电阻抗分析测四肢骨骼肌质量指数,握力计测肌力。
- 收集人口学、临床参数及用药情况,使用SPSS V.21.0进行统计分析。
主要发现
- RA患者肌少症总体患病率为18.6%(182/978)。
- 男性与肌少症相关(OR 9.140,95% CI 5.211至16.029)。
- BMI与肌少症相关(OR 0.586,95% CI 0.534至0.643)。
- 病程与肌少症相关(OR 1.046,95% CI 1.025至1.069)。
- RF-IgM水平与肌少症相关(OR 1.002,95% CI 1.000至1.003)。
关键数值与推荐
- 泼尼松剂量与肌少症相关(OR 1.094,95% CI 1.033至1.159)。
- TNF抑制剂使用与肌少症相关(OR 0.502,95% CI 0.312至0.808)。
- 托珠单抗使用与肌少症相关(OR 0.493,95% CI 0.304至0.799)。
临床怎么用
- 对RA患者,尤其男性、低BMI、长病程、高RF-IgM或高泼尼松剂量者,应关注肌少症筛查。
- 使用TNF抑制剂或托珠单抗可能有助于降低肌少症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)-driven in part by chronic inflammation-and is linked to a poor prognosis. This study aimed to investigate the prevalence of sarcopenia in patients with RA using Asian Working Group for Sarcopenia (AWGS) 2025 criteria and to analyse its associated clinical features. METHODS: This cross-sectional study enrolled 978 patients with RA (mean age 60.1±12.1 years, range 21-99 years and 86.4% female) diagnosed according to the 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria. Sarcopenia was diagnosed based on the AWGS 2025 consensus, using bioelectrical impedance analysis for appendicular skeletal muscle mass index, handgrip dynamometry for muscle strength. Demographic data, clinical parameters and medication use were collected. Statistical analysis was performed using SPSS V.21.0. RESULTS: The overall prevalence of sarcopenia among patients with RA was 18.6% (182/978). Male gender (OR 9.140, 95% CI 5.211 to 16.029), body mass index (BMI) (OR 0.586, 95% CI 0.534 to 0.643), disease duration (OR 1.046, 95% CI 1.025 to 1.069), rheumatoid factor (RF)-IgM level (OR 1.002, 95% CI 1.000 to 1.003), prednisone dosage (OR 1.094, 95% CI 1.033 to 1.159), tumour necrosis factor inhibitors (TNF-i) use (OR 0.502, 95% CI 0.312 to 0.808) and tocilizumab use (OR 0.493, 95% CI 0.304 to 0.799) were associated with sarcopenia in patients with RA. CONCLUSION: The prevalence of sarcopenia is considerable in patients with RA. Key risk factors include male gender, lower BMI, longer disease duration, higher RF-IgM level and higher dosage of glucocorticoid use. The use of tocilizumab and TNF-i may be associated with a reduced incidence of sarcopenia in this population.
引用
- Wang H, Xu J, Li Y, et al. Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study. RMD Open. 2026. PMID: 42399074. doi:10.1136/rmdopen-2026-006945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。